BioMarin Pharmaceutical (BSP:B1MR34) Inventories, Raw Materials & Components: R$512 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:B1MR34 BioMarin Pharmaceutical Inc BSP:B1MR34
69 GF Score
Price R$148.95
GF Value R$240.34
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is BioMarin Pharmaceutical Inventories, Raw Materials & Components?

BioMarin Pharmaceutical BSP:B1MR34 69 Inventories, Raw Materials & Components is R$512 Mil as of Mar. 2026. GuruFocus rates BSP:B1MR34 with a GF Score™ of 69/100 and a GF Value™ of R$240.34 (Significantly Undervalued). The stock has 3 warning signs investors should review.

BioMarin Pharmaceutical's inventories, raw materials & components for the quarter that ended in Mar. 2026 was R$512 Mil.

BioMarin Pharmaceutical's quarterly raw materials declined from Sep. 2025 (R$618 Mil) to Dec. 2025 (R$581 Mil) and declined from Dec. 2025 (R$581 Mil) to Mar. 2026 (R$512 Mil).

BioMarin Pharmaceutical's annual raw materials increased from Dec. 2023 (R$763 Mil) to Dec. 2024 (R$942 Mil) but then declined from Dec. 2024 (R$942 Mil) to Dec. 2025 (R$581 Mil).

BioMarin Pharmaceutical Inventories, Raw Materials & Components Historical Data

* Premium members only.

The historical data trend for BioMarin Pharmaceutical's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioMarin Pharmaceutical Inventories, Raw Materials & Components Chart

BioMarin Pharmaceutical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Raw Materials & Components
Get a 7-Day Free Trial Premium Member Only Premium Member Only 453.91 687.52 762.92 941.63 581.09

BioMarin Pharmaceutical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 935.65 664.13 618.37 581.09 511.72
BSP:B1MR34
69GF Score
BioMarin Pharmaceutical Inc BSP:B1MR34
Inventories, Raw Materials & Components is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioMarin Pharmaceutical Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.

What does a Inventories, Raw Materials & Components of R$512 Mil mean?
BioMarin Pharmaceutical (BSP:B1MR34) has a Inventories, Raw Materials & Components of R$512 Mil as of Mar. 2026. Raw materials are the components a company uses for its main products. View historical data on BioMarin Pharmaceutical and its competitors.
Is BioMarin Pharmaceutical's Inventories, Raw Materials & Components too high?
BioMarin Pharmaceutical's current Inventories, Raw Materials & Components is R$512 Mil. Overall, BioMarin Pharmaceutical has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioMarin Pharmaceutical's Inventories, Raw Materials & Components compare to CYTK and ARWR?
BioMarin Pharmaceutical's Inventories, Raw Materials & Components of R$512 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Raw Materials & Components for a Biotechnology company?
A good Inventories, Raw Materials & Components depends on the Biotechnology industry context. However, Inventories, Raw Materials & Components should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Raw Materials & Components mean?
A high Inventories, Raw Materials & Components can signal that a stock is expensive relative to its fundamentals. Raw materials are the components a company uses for its main products. View historical data on BioMarin Pharmaceutical and its competitors. BioMarin Pharmaceutical's current Inventories, Raw Materials & Components is R$512 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMarin Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, BioMarin Pharmaceutical (BSP:B1MR34) is currently considered Significantly Undervalued. The stock's GF Value™ is R$240.34, compared to a current price of R$148.95 — trading 38% below its estimated fair value. The current Inventories, Raw Materials & Components is R$512 Mil. BioMarin Pharmaceutical's overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Raw Materials & Components calculated?
Inventories, Raw Materials & Components is calculated from a company's financial statements. For BioMarin Pharmaceutical (BSP:B1MR34), the current Inventories, Raw Materials & Components is R$512 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioMarin Pharmaceutical (BSP:B1MR34) Overvalued in 2026?

Based on GuruFocus' analysis, BioMarin Pharmaceutical stock appears to be undervalued. The current stock price of R$148.95 is trading 38% below its estimated GF Value™ of R$240.34. GuruFocus considers BioMarin Pharmaceutical to be Significantly Undervalued.

Key valuation signals for BSP:B1MR34:

  • Inventories, Raw Materials & Components: R$512 Mil
  • GF Value™: R$240.34 vs. price of R$148.95 (38% below fair value)
  • GF Score™: 69/100 with 3 warning signs

No single metric tells the full story. See the BSP:B1MR34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioMarin Pharmaceutical Business Description

Address 770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
69GF Score

Get the complete analysis for BSP:B1MR34

Inventories, Raw Materials & Components is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$148.95
Price
R$240.34
GF Value